Gilead Sciences, Inc. (NASDAQ:GILD) Shares Bought by Mutual of America Capital Management LLC

Mutual of America Capital Management LLC lifted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 0.3% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 179,205 shares of the biopharmaceutical company’s stock after buying an additional 580 shares during the period. Mutual of America Capital Management LLC’s holdings in Gilead Sciences were worth $12,295,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Axxcess Wealth Management LLC raised its position in Gilead Sciences by 10.2% in the second quarter. Axxcess Wealth Management LLC now owns 19,746 shares of the biopharmaceutical company’s stock worth $1,355,000 after acquiring an additional 1,830 shares in the last quarter. Alpha Family Trust grew its stake in shares of Gilead Sciences by 28.4% in the 2nd quarter. Alpha Family Trust now owns 9,315 shares of the biopharmaceutical company’s stock worth $639,000 after purchasing an additional 2,060 shares during the last quarter. Excalibur Management Corp raised its holdings in shares of Gilead Sciences by 4.7% in the 2nd quarter. Excalibur Management Corp now owns 23,943 shares of the biopharmaceutical company’s stock worth $1,643,000 after purchasing an additional 1,081 shares in the last quarter. Renaissance Technologies LLC lifted its stake in Gilead Sciences by 17.1% during the second quarter. Renaissance Technologies LLC now owns 5,057,598 shares of the biopharmaceutical company’s stock valued at $347,002,000 after purchasing an additional 739,948 shares during the last quarter. Finally, Citizens Financial Group Inc. RI boosted its holdings in Gilead Sciences by 36.1% during the second quarter. Citizens Financial Group Inc. RI now owns 5,984 shares of the biopharmaceutical company’s stock worth $411,000 after buying an additional 1,588 shares in the last quarter. 83.67% of the stock is owned by institutional investors.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 5,490 shares of the company’s stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $73.98, for a total transaction of $406,150.20. Following the completion of the sale, the insider now owns 114,979 shares of the company’s stock, valued at $8,506,146.42. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $68.63, for a total value of $137,260.00. Following the transaction, the insider now directly owns 96,380 shares in the company, valued at $6,614,559.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Johanna Mercier sold 5,490 shares of the stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $73.98, for a total value of $406,150.20. Following the sale, the insider now owns 114,979 shares of the company’s stock, valued at approximately $8,506,146.42. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 36,847 shares of company stock valued at $3,002,940. Corporate insiders own 0.16% of the company’s stock.

Gilead Sciences Stock Up 1.0 %

Shares of Gilead Sciences stock opened at $83.89 on Thursday. The company has a debt-to-equity ratio of 1.18, a current ratio of 1.14 and a quick ratio of 0.95. The firm has a market cap of $104.51 billion, a price-to-earnings ratio of 233.03, a P/E/G ratio of 2.80 and a beta of 0.18. The stock has a 50-day simple moving average of $76.40 and a 200-day simple moving average of $71.09. Gilead Sciences, Inc. has a 52-week low of $62.07 and a 52-week high of $87.86.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, beating analysts’ consensus estimates of $1.61 by $0.40. The business had revenue of $6.95 billion for the quarter, compared to the consensus estimate of $6.64 billion. Gilead Sciences had a net margin of 3.79% and a return on equity of 29.34%. On average, equities research analysts expect that Gilead Sciences, Inc. will post 3.78 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 27th. Stockholders of record on Friday, September 13th will be issued a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a dividend yield of 3.67%. The ex-dividend date is Friday, September 13th. Gilead Sciences’s dividend payout ratio is 855.56%.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on GILD shares. Truist Financial increased their price objective on Gilead Sciences from $82.00 to $83.00 and gave the company a “hold” rating in a research report on Thursday, August 15th. Piper Sandler reaffirmed an “overweight” rating and set a $95.00 target price on shares of Gilead Sciences in a report on Wednesday, September 11th. Royal Bank of Canada increased their price target on Gilead Sciences from $72.00 to $74.00 and gave the company a “sector perform” rating in a research report on Wednesday, September 4th. Evercore ISI upgraded Gilead Sciences to a “strong-buy” rating in a report on Friday, August 9th. Finally, Robert W. Baird reiterated a “neutral” rating and issued a $80.00 target price on shares of Gilead Sciences in a report on Thursday, June 20th. Twelve analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $82.06.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.